Dorsamy Pillay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dorsamy Pillay has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
Balakrishna Pillay
9 shared publications- Ademola Olufolahan Olaniran
Department of Microbiology, School of Life Sciences University of KwaZulu‐Natal Durban South Africa
7 shared publications - Bonaventura Clotet
IrsiCaixa, Badalona, Spain
7 shared publications - Daniel Robert Kuritzkes
Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School , Boston, Massachusetts
7 shared publications Jonathan M Schapiro
7 shared publicationsVictoria A Johnson
7 shared publications
Latest Publications
- Open Access
- 28 May 2024
- Published by Academy of Science of South Africa in South African Journal of Science
- Vol. 120 (5/6)
Why researchers should focus on the triple bottom line: Excellence, ethics and empathy
- 28 May 2024
- Published by Academy of Science of South Africa in South African Journal of Science
- Vol. 120 (5/6)
Open AccessWhy researchers should focus on the triple bottom line: Excellence, ethics and empathy
- 1 March 2016
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 22 (3) , 244-251
Gram-negative bacteraemia; a multi-centre prospective evaluation of empiric antibiotic therapy and outcome in English acute hospitals
- 1 March 2016
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 22 (3) , 244-251
Gram-negative bacteraemia; a multi-centre prospective evaluation of empiric antibiotic therapy and outcome in English acute hospitals
- 1 March 2013
- Published by Elsevier in Infection, Genetics and Evolution
- Vol. 14, 232-239
Phylogenetic and demographic characterization of HIV-1 transmission in Madrid, Spain
- 1 March 2013
- Published by Elsevier in Infection, Genetics and Evolution
- Vol. 14, 232-239
Phylogenetic and demographic characterization of HIV-1 transmission in Madrid, Spain
- Open Access
- 15 February 2012
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 205 (4) , 540-547
Does Discordancy Between the CD4 Count and CD4 Percentage in HIV-Positive Individuals Influence Outcomes on Highly Active Antiretroviral Therapy?
Introduction. The CD4 count and CD4 percentage (CD4%) are both strong predictors of clinical disease progression in human immunodeficiency virus (HIV). Although individuals may show discordancy between their CD4 count and CD4%, the clinical relevance of this is unclear. Methods. Discordancy was defined where the CD4% was ≤10th percentile for a selected CD4 count range (referred to as low discordancy), within the central 80% range (concordant), or ≥90th percentile (high discordancy). Regression methods identified factors associated with low and high discordancy in untreated individuals and assessed the impact of discordancy on treatment responses to highly active antiretroviral therapy (HAART). Results. High discordancy was associated with female sex, low viral load, and white ethnicity; low discordancy was associated with black or nonwhite ethnicity, older age, and injection drug use. Clinical event rates were higher in individuals with high discordancy starting HAART, but there was no association with subsequent HIV progression by 6 months after starting HAART. CD4 count increases remained lower, by 20 cells/mm3, in individuals with low discordancy, and higher, by 27 cells/mm3, in those with high discordancy. Conclusions. Overall discrepancies between the CD4/CD4% are small, confirming the use of absolute CD4 counts as a monitoring tool.
- 15 February 2012
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 205 (4) , 540-547
Open AccessDoes Discordancy Between the CD4 Count and CD4 Percentage in HIV-Positive Individuals Influence Outcomes on Highly Active Antiretroviral Therapy?
Introduction. The CD4 count and CD4 percentage (CD4%) are both strong predictors of clinical disease progression in human immunodeficiency virus (HIV). Although individuals may show discordancy between their CD4 count and CD4%, the clinical relevance of this is unclear. Methods. Discordancy was defined where the CD4% was ≤10th percentile for a selected CD4 count range (referred to as low discordancy), within the central 80% range (concordant), or ≥90th percentile (high discordancy). Regression methods identified factors associated with low and high discordancy in untreated individuals and assessed the impact of discordancy on treatment responses to highly active antiretroviral therapy (HAART). Results. High discordancy was associated with female sex, low viral load, and white ethnicity; low discordancy was associated with black or nonwhite ethnicity, older age, and injection drug use. Clinical event rates were higher in individuals with high discordancy starting HAART, but there was no association with subsequent HIV progression by 6 months after starting HAART. CD4 count increases remained lower, by 20 cells/mm3, in individuals with low discordancy, and higher, by 27 cells/mm3, in those with high discordancy. Conclusions. Overall discrepancies between the CD4/CD4% are small, confirming the use of absolute CD4 counts as a monitoring tool.
- 5 December 2011
- Published by Taylor & Francis
- p. 455-479
Biofuels and Biochemicals in Africa
- 1 December 2010
- Vol. 18 (5) , 156-63
Update of the drug resistance mutations in HIV-1: December 2010.
This December 2010 version of the International AIDS Society-USA (IAS-USA) drug resistance mutations list updates the figures last published in December 2009 (Johnson VA et al, Top HIV Med, 2009;17:138-145). This update includes 9 new mutations- E138G and E138K for etravirine (Haddad M et al, CROI, 2010; Abstract 574, and Vingerhoets J et al, Antivir Ther, 2010;15 [Suppl 2]:A125); E92Q for raltegravir (Geretti AM et al, Antivir Ther, 2010;15 [Suppl 2]:A62; Cooper et al, N Engl J Med, 2008;359:355-365; and Malet I et al, Antimicrob Agents Chemother, 2008;52:1351-1358); and M36L, M36V, H69R, L89I, L89M, and L89V for tipranavir/ritonavir. In addition, the tipranavir/ritonavir N83D mutation designation was changed to boldface to indicate its recognition as a major mutation rather than a minor mutation. The mutations I13V, K20M/R, E35G, and L90M were removed from the tipranavir/ritonavir bar, reflecting new understanding. For etravirine, L100I*, K101P*, and Y181C*/I*/V* are denoted with asterisks (instead of bolded) to reflect that these individual mutations each have the greatest impact (ie, highest weighting scores) on reduced phenotypic susceptibility and impaired clinical response when compared with other etravirine mutations (Haddad M et al, CROI, 2010; Abstract 574). In addition, user notes d, n, r, w, and z were revised.
- 1 December 2010
- Vol. 18 (5) , 156-63
Update of the drug resistance mutations in HIV-1: December 2010.
This December 2010 version of the International AIDS Society-USA (IAS-USA) drug resistance mutations list updates the figures last published in December 2009 (Johnson VA et al, Top HIV Med, 2009;17:138-145). This update includes 9 new mutations- E138G and E138K for etravirine (Haddad M et al, CROI, 2010; Abstract 574, and Vingerhoets J et al, Antivir Ther, 2010;15 [Suppl 2]:A125); E92Q for raltegravir (Geretti AM et al, Antivir Ther, 2010;15 [Suppl 2]:A62; Cooper et al, N Engl J Med, 2008;359:355-365; and Malet I et al, Antimicrob Agents Chemother, 2008;52:1351-1358); and M36L, M36V, H69R, L89I, L89M, and L89V for tipranavir/ritonavir. In addition, the tipranavir/ritonavir N83D mutation designation was changed to boldface to indicate its recognition as a major mutation rather than a minor mutation. The mutations I13V, K20M/R, E35G, and L90M were removed from the tipranavir/ritonavir bar, reflecting new understanding. For etravirine, L100I*, K101P*, and Y181C*/I*/V* are denoted with asterisks (instead of bolded) to reflect that these individual mutations each have the greatest impact (ie, highest weighting scores) on reduced phenotypic susceptibility and impaired clinical response when compared with other etravirine mutations (Haddad M et al, CROI, 2010; Abstract 574). In addition, user notes d, n, r, w, and z were revised.
- Open Access
- 14 October 2010
- Published by Wiley in HIV Medicine
- Vol. 12 (4) , 250-254
Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance*
Objectives The aim of the study was to estimate the levels of transmitted drug resistance (TDR) in HIV‐1 using very sensitive assays to detect minority drug‐resistant populations. Methods We tested unlinked anonymous serum specimens from sexual health clinic attendees, who had not received an HIV diagnosis at the time of sampling, by both standard genotyping and using minority detection assays. Results By standard genotyping, 21 of 165 specimens (12.7%) showed evidence of drug resistance, while, using a combination of standard genotyping and minority mutation assays targeting three commonly observed drug resistance mutations which cause high‐level resistance to commonly prescribed first‐line antiretroviral therapy (ART), this rose to 32 of 165 (19.4%). This increase of 45% in drug resistance levels [95% confidence interval (CI) 15.2–83.7%; P=0.002] was statistically significant. Almost all of this increase was accounted for by additional detections of the M184V mutation. Conclusions Future surveillance studies of TDR in the United Kingdom should consider combining standard genotyping and minority‐specific assays to provide more accurate estimates, particularly when using specimens collected from chronic HIV infections in which TDR variants may have declined to low levels.
- 14 October 2010
- Published by Wiley in HIV Medicine
- Vol. 12 (4) , 250-254
Open AccessIncreased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance*
Objectives The aim of the study was to estimate the levels of transmitted drug resistance (TDR) in HIV‐1 using very sensitive assays to detect minority drug‐resistant populations. Methods We tested unlinked anonymous serum specimens from sexual health clinic attendees, who had not received an HIV diagnosis at the time of sampling, by both standard genotyping and using minority detection assays. Results By standard genotyping, 21 of 165 specimens (12.7%) showed evidence of drug resistance, while, using a combination of standard genotyping and minority mutation assays targeting three commonly observed drug resistance mutations which cause high‐level resistance to commonly prescribed first‐line antiretroviral therapy (ART), this rose to 32 of 165 (19.4%). This increase of 45% in drug resistance levels [95% confidence interval (CI) 15.2–83.7%; P=0.002] was statistically significant. Almost all of this increase was accounted for by additional detections of the M184V mutation. Conclusions Future surveillance studies of TDR in the United Kingdom should consider combining standard genotyping and minority‐specific assays to provide more accurate estimates, particularly when using specimens collected from chronic HIV infections in which TDR variants may have declined to low levels.
- 1 December 2009
- Vol. 17 (5) , 138-45
Update of the drug resistance mutations in HIV-1: December 2009.
- 1 December 2009
- Vol. 17 (5) , 138-45
Update of the drug resistance mutations in HIV-1: December 2009.
- Open Access
- 1 September 2009
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 200 (5) , 710-714
Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir
Patients with a baseline viral load >100,000 copies/mL receiving abacavir (ABC) as part of the nucleoside-backbone component of their first highly active antiretroviral therapy (HAART) regimen have been reported to have a greater failure rate than those receiving tenofovir (TDF). We analyzed short-term outcomes of the use of HAART combinations that included ABC or TDF. The mean 2–8-week change in viral load was calculated using linear regression. In total, 1136 patients started ABC, and 412 started TDF. After adjustment for baseline viral load and other factors, there was no difference in the change in viral load between the patients who started ABC and those who started TDF (0.03 [95% confidence interval, −0.07 to 0.12]) log copies/mL; P=.59). Furthermore, there was no evidence that this effect differed according to baseline viral load (P=.88 for the interaction between pre-HAART viral load and nucleoside started). Likewise, there was no difference in rates of virological failure between the 2 drugs at 24–48 weeks after starting HAART
- 1 September 2009
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 200 (5) , 710-714
Open AccessVirological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir
Patients with a baseline viral load >100,000 copies/mL receiving abacavir (ABC) as part of the nucleoside-backbone component of their first highly active antiretroviral therapy (HAART) regimen have been reported to have a greater failure rate than those receiving tenofovir (TDF). We analyzed short-term outcomes of the use of HAART combinations that included ABC or TDF. The mean 2–8-week change in viral load was calculated using linear regression. In total, 1136 patients started ABC, and 412 started TDF. After adjustment for baseline viral load and other factors, there was no difference in the change in viral load between the patients who started ABC and those who started TDF (0.03 [95% confidence interval, −0.07 to 0.12]) log copies/mL; P=.59). Furthermore, there was no evidence that this effect differed according to baseline viral load (P=.88 for the interaction between pre-HAART viral load and nucleoside started). Likewise, there was no difference in rates of virological failure between the 2 drugs at 24–48 weeks after starting HAART
- 1 January 2009
- Published by Elsevier in Journal of Microbiological Methods
- Vol. 76 (1) , 43-51
Amplified fragment length polymorphisms reveal genetic differentiation among strains of Xanthomonas albilineans
- 1 January 2009
- Published by Elsevier in Journal of Microbiological Methods
- Vol. 76 (1) , 43-51
Amplified fragment length polymorphisms reveal genetic differentiation among strains of Xanthomonas albilineans